Immunovant, Inc. Net Income Loss

• Immunovant, Inc. showed a decrease of -59.6% in Net Income Loss from 2024 to 2025.
• This data is from Immunovant, Inc.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Immunovant, Inc.'s Net Income Loss has declined by 1,347.0%.
• Historical annual values: Fiscal year 2025: -$413.84 million | Fiscal year 2024: -$259.34 million | Fiscal year 2023: -$210.96 million | Fiscal year 2022: -$156.73 million | Fiscal year 2021: -$107.43 million | Fiscal year 2020: -$66.39 million | Fiscal year 2019: -$28.60 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026